大麻隆结构式
|
常用名 | 大麻隆 | 英文名 | (−)-nabilone |
---|---|---|---|---|
CAS号 | 51022-71-0 | 分子量 | 372.541 | |
密度 | 1.0±0.1 g/cm3 | 沸点 | 457.4±45.0 °C at 760 mmHg | |
分子式 | C24H36O3 | 熔点 | 155-156ºC | |
MSDS | 美版 | 闪点 | 145.4±22.2 °C | |
符号 |
GHS07 |
信号词 | Warning |
中文名 | 纳比隆 |
---|---|
英文名 | (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one |
中文别名 | 反式-6,6-二甲基-3-(1,1-二甲基庚基)-1-羟基-6,6a,7,8,10,10a-六氢-9H-二苯并[b,d]吡喃-9-酮 | 纳必龙 | 大麻隆 |
英文别名 | 更多 |
密度 | 1.0±0.1 g/cm3 |
---|---|
沸点 | 457.4±45.0 °C at 760 mmHg |
熔点 | 155-156ºC |
分子式 | C24H36O3 |
分子量 | 372.541 |
闪点 | 145.4±22.2 °C |
精确质量 | 372.266449 |
PSA | 46.53000 |
LogP | 7.05 |
外观性状 | 白色固体 |
蒸汽压 | 0.0±1.2 mmHg at 25°C |
折射率 | 1.517 |
储存条件 | 2-8°C |
水溶解性 | DMSO: ~18 mg/mL, soluble |
符号 |
GHS07 |
---|---|
信号词 | Warning |
危害声明 | H302 |
个人防护装备 | dust mask type N95 (US);Eyeshields;Gloves |
危害码 (欧洲) | Xn: Harmful; |
风险声明 (欧洲) | R22 |
安全声明 (欧洲) | 36/37/39-45 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
RTECS号 | HP8756000 |
Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain.
Expert Opin. Investig. Drugs 17(1) , 85-95, (2008) Nabilone has been approved to treat chemotherapy-induced nausea and vomiting. Recent studies have explored cannabinoids in pain management.To review the evidence for the use of cannabinoids in general... |
|
A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury.
Arch. Phys. Med. Rehabil. 91(5) , 703-7, (2010) To determine whether nabilone, a synthetic cannabinoid, alleviates spasticity in people with spinal cord injury (SCI).A double-blind, placebo-controlled crossover study.Outpatient rehabilitation clini... |
|
An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy.
Pain Pract. 11(4) , 353-68, (2011) Neuropathic pain (NeP) is prevalent in patients with peripheral neuropathy (PN), regardless of etiology. We sought to compare the efficacy of the cannabinoid nabilone as either monotherapy or adjuvant... |
9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel- |
UNII:2N4O9L084N |
trans-(±)-3-(1,1-Dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one |
Compound 109514 |
nabilone |
Nabilonum |
(6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-one |
9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)- |
(6aR,10aR)-nabilone |
Cesamet |
Nabilon |
Nabilone (USAN/INN) |
(6aR,10aR)-3-(1,1-Dimethylheptyl)-1-hydroxy-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-on |
(6aR,10aR)-3-(1,1-diméthylheptyl)-1-hydroxy-6,6-diméthyl-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromén-9-one |
Cesamet (TN) |
(6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-one |
Nabilona |
(6aR,10aR)-3-(1,1-dimethylheptyl)-1-hydroxy-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-one |